A citation-based method for searching scientific literature

Fabrizio Tabbò, Chiara Pisano, Julien Mazieres, Laura Mezquita, Ernest Nadal, David Planchard, Anne Pradines, David Santamaria, Aurélie Swalduz, Chiara Ambrogio, Silvia Novello, Sandra Ortiz-Cuaran. Cancer Treat Rev 2022
Times Cited: 2







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
David Planchard, Egbert F Smit, Harry J M Groen, Julien Mazieres, Benjamin Besse, Åslaug Helland, Vanessa Giannone, Anthony M D'Amelio, Pingkuan Zhang, Bijoyesh Mookerjee,[...]. Lancet Oncol 2017
476
100

BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
Karim Rihawi, Diana Giannarelli, Domenico Galetta, Angelo Delmonte, Marco Giavarra, Daniele Turci, Marina Garassino, Marcello Tiseo, Fausto Barbieri, Stefano Panni,[...]. J Thorac Oncol 2019
23
100

BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, Shoshana Keren, Noa Popovits-Hadari, Damien Urban,[...]. J Thorac Oncol 2018
102
100

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Alessandro Leonetti, Francesco Facchinetti, Giulio Rossi, Roberta Minari, Antonia Conti, Luc Friboulet, Marcello Tiseo, David Planchard. Cancer Treat Rev 2018
73
100

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.
David Planchard, Benjamin Besse, Harry J M Groen, Sayed M S Hashemi, Julien Mazieres, Tae Min Kim, Elisabeth Quoix, Pierre-Jean Souquet, Fabrice Barlesi, Christina Baik,[...]. J Thorac Oncol 2022
25
100

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
474
100

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
David Planchard, Benjamin Besse, Harry J M Groen, Pierre-Jean Souquet, Elisabeth Quoix, Christina S Baik, Fabrice Barlesi, Tae Min Kim, Julien Mazieres, Silvia Novello,[...]. Lancet Oncol 2016
500
100

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.
Paul T C Wan, Mathew J Garnett, S Mark Roe, Sharlene Lee, Dan Niculescu-Duvaz, Valerie M Good, C Michael Jones, Christopher J Marshall, Caroline J Springer, David Barford,[...]. Cell 2004
50

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paul K Paik, Maria E Arcila, Michael Fara, Camelia S Sima, Vincent A Miller, Mark G Kris, Marc Ladanyi, Gregory J Riely. J Clin Oncol 2011
468
50

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Matthew Dankner, April A N Rose, Shivshankari Rajkumar, Peter M Siegel, Ian R Watson. Oncogene 2018
180
50

Raf-1 protein kinase is required for growth of induced NIH/3T3 cells.
W Kolch, G Heidecker, P Lloyd, U R Rapp. Nature 1991
486
50

Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.
Irena Tan, Thomas E Stinchcombe, Neal E Ready, Jeffrey Crawford, Michael B Datto, Rebecca J Nagy, Richard B Lanman, Lin Gu, Jeffrey M Clarke. Transl Lung Cancer Res 2019
13
50

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients.
Umberto Malapelle, Giulio Rossi, Pasquale Pisapia, Massimo Barberis, Fiamma Buttitta, Francesca Castiglione, Fabiana Letizia Cecere, Antonio Maria Grimaldi, Antonino Iaccarino, Antonio Marchetti,[...]. Crit Rev Oncol Hematol 2020
9
50

Mutations of the BRAF gene in human cancer.
Helen Davies, Graham R Bignell, Charles Cox, Philip Stephens, Sarah Edkins, Sheila Clegg, Jon Teague, Hayley Woffendin, Mathew J Garnett, William Bottomley,[...]. Nature 2002
50

The Raf/MEK/ERK pathway: new concepts of activation.
C Peyssonnaux, A Eychène. Biol Cell 2001
565
50

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.
Antonio Marchetti, Lara Felicioni, Sara Malatesta, Maria Grazia Sciarrotta, Luigi Guetti, Antonio Chella, Patrizia Viola, Carmela Pullara, Felice Mucilli, Fiamma Buttitta. J Clin Oncol 2011
364
50

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.
Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y Yeap, Lynette M Sholl, Bruce E Johnson, Pasi A Jänne. Clin Cancer Res 2013
241
50

Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
Xi Ding, Zengli Zhang, Tao Jiang, Xuefei Li, Chao Zhao, Bo Su, Caicun Zhou. Cancer Med 2017
31
50

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Zhan Yao, Neilawattie M Torres, Anthony Tao, Yijun Gao, Lusong Luo, Qi Li, Elisa de Stanchina, Omar Abdel-Wahab, David B Solit, Poulikos I Poulikakos,[...]. Cancer Cell 2015
274
50

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
750
50

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
36
50

Expression of raf oncogenes activates the PEA1 transcription factor motif.
C Wasylyk, B Wasylyk, G Heidecker, M Huleihel, U R Rapp. Mol Cell Biol 1989
121
50

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Alessandro Russo, Ana Rita Lopes, Michael G McCusker, Sandra Gimenez Garrigues, Giuseppina R Ricciardi, Katherine E Arensmeyer, Katherine A Scilla, Ranee Mehra, Christian Rolfo. Curr Oncol Rep 2020
27
50

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.
Anya M Litvak, Paul K Paik, Kaitlin M Woo, Camelia S Sima, Matthew D Hellmann, Maria E Arcila, Marc Ladanyi, Charles M Rudin, Mark G Kris, Gregory J Riely. J Thorac Oncol 2014
84
50

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Dong Chen, Li-Qun Zhang, Jun-Fu Huang, Kai Liu, Zheng-Ran Chuai, Zhao Yang, Yun-Xia Wang, Da-Chuan Shi, Qian Liu, Qing Huang,[...]. PLoS One 2014
68
50


A note on quantifying follow-up in studies of failure time.
M Schemper, T L Smith. Control Clin Trials 1996
50

Detection of BRAF V600E mutation by pyrosequencing.
Yi Hui Tan, Yanqun Liu, Kong Weng Eu, Pei Woon Ang, Wei Qi Li, Manuel Salto-Tellez, Barry Iacopetta, Richie Soong. Pathology 2008
69
50

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, Alexandre Reuben, Miles C Andrews, Merrick I Ross, Isabella C Glitza, Janice Cormier, Wen-Jen Hwu, Hussein A Tawbi,[...]. Lancet Oncol 2018
155
50


Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials.
Li Sun, Yi-Jia Guo, Jun Song, Yan-Ru Wang, Shu-Ling Zhang, Le-Tian Huang, Jian-Zhu Zhao, Wei Jing, Cheng-Bo Han, Jie-Tao Ma. Front Oncol 2021
24
50

Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
Priscilla K Brastianos, Ganesh M Shankar, Corey M Gill, Amaro Taylor-Weiner, Naema Nayyar, David J Panka, Ryan J Sullivan, Dennie T Frederick, Malak Abedalthagafi, Pamela S Jones,[...]. J Natl Cancer Inst 2015
139
50

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.
Li Liu, Patrick A Mayes, Stephen Eastman, Hong Shi, Sapna Yadavilli, Tianqian Zhang, Jingsong Yang, Laura Seestaller-Wehr, Shu-Yun Zhang, Chris Hopson,[...]. Clin Cancer Res 2015
283
50

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
112
50


Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma.
Jennifer R Wang, Mark E Zafereo, Ramona Dadu, Renata Ferrarotto, Naifa L Busaidy, Charles Lu, Salmaan Ahmed, Maria K Gule-Monroe, Michelle D Williams, Erich M Sturgis,[...]. Thyroid 2019
85
50

BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts.
Daofu Feng, Bo Qin, Krishnendu Pal, Lei Sun, Shamit Dutta, Haidong Dong, Xin Liu, Debabrata Mukhopadhyay, Shengbing Huang, Frank A Sinicrope. Oncogene 2019
36
50

Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
Alessandro Leonetti, Roberta Minari, Luca Boni, Letizia Gnetti, Michela Verzè, Luigi Ventura, Luca Musini, Michele Tognetto, Marcello Tiseo. Clin Lung Cancer 2021
9
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.